Delivery Order SPE2DB24D2105-SPE2DB25FAPZW
- Not listed
- The Defense Logistics Agency awarded a $10,974.69 delivery order to AmerisourceBergen Drug Corp for Briviact 100 mg tablets (60-count units) under a firm fixed price contract. The award was made on August 1, 2025, with an ultimate completion date of August 4, 2025, and represents a non-competitive, non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same municipality. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a $1,905.41 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Briviact 25 mg on July 21, 2025, with a completion date of July 22, 2025. This is a firm fixed-price delivery order issued under a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting military and...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order valued at $1,002.64 to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Briviact 100 mg tablets (60-count units). This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 24, 2025, with performance to occur at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $4,653.35 to AmerisourceBergen Drug Corp for Briviact 25 mg tablets (60-count units) on July 25, 2025, with completion targeted for July 28, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $5,569.98 to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Briviact 50 mg tablets (60-count units). This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is scheduled for completion by July 28, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $913.50 firm fixed price delivery order to Amerisourcebergen Drug Corporation for the supply of 50 mg Briviact tablets. Under this single award, Amerisourcebergen will deliver 60 tablets to a facility in Conshohocken, Pennsylvania by June 27, 2023 to support the DLA's medical supply needs. As a top 10 Defense Department contractor, Amerisourcebergen frequently provides pharmaceuticals and medical supplies to DLA under the agency's Prime Vendor Next contract...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $3,763.04 firm fixed price delivery order contract to AmerisourceBergen Drug Corp's Corporate Office division. The contract is to provide 4,565,266,227 units of the pharmaceutical product BRIVIACT 100 MG TABLET 60S. This delivery order is not set aside and has an ultimate completion date of July 29, 2024. AmerisourceBergen Drug Corp, one of the largest pharmaceutical distributors in the U.S., has been awarded numerous...
- The Defense Logistics Agency awarded a $6,313.32 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 60 tablets of Briviact 50 mg, with an ultimate completion date of August 4, 2025. This non-set-aside contract was awarded on August 1, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, was selected through competitive...
- The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to Amerisourcebergen Drug Corp, a pharmaceutical distribution subsidiary of Amerisourcebergen Corporation. The $1,705.58 firm fixed-price contract is for the supply of Briviact 10 mg/ml oral solution in 300 ml bottles, with a period of performance through May 13, 2024. Amerisourcebergen holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as the primary vehicle...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation's Corporate Office division. The $11,595.24 firm fixed-price delivery order is for the supply of Briviact 50 mg tablets, a pharmaceutical product. The contract has an ultimate completion date of August 28, 2024 and is not designated as a set-aside. AmerisourceBergen, a major pharmaceutical distributor, holds a significant Indefinite Delivery Contract (IDC) with...
- SPE2DB24D2105Indefinite Delivery Contract
- SPE2DB24D2105-SPE2DB25FAPZWDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Briviact 50 mg tablets (60-count units) valued at $2,241.28 under a firm fixed price contract type. The delivery order was competitively awarded without set-aside designation and is scheduled for completion by August 4, 2025. AmerisourceBergen will fulfill this order from its corporate office location in Conshohocken, Pennsylvania, serving as a critical pharmaceutical supplier to federal medical procurement needs. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion comprehensive global pharmaceutical support vehicle running through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that serves as a key vendor for federal medical supply chains, particularly supporting military and veteran healthcare systems. The company's extensive contract portfolio with the DLA demonstrates its capability to supply a comprehensive range of pharmaceutical products, medical devices, and specialized healthcare commodities across multiple therapeutic domains. The parent IDC enables the company to deliver critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, and medical supplies to customers including the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems on a flexible, as-needed basis.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 8/1/25 |